Eli Lilly News - Search News

Eli Lilly shares drop

CNBC on MSN · 2d

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

YAHOO!Finance · 2d

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.

invezz on MSN · 1d

Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches boosting long-term growth.

Crohn's disease, FDA and Lilly

Reuters on MSN · 21h

US FDA approves expanded use of Lilly's bowel disease drug

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease (IBD). The drug, branded as Omvoh,

Business Insider · 19h

FDA Approves Lilly's Omvoh For Crohn's Disease Treatment

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment

Lilly’s Omvoh approved by FDA for Crohn’s

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success in diabetes and obesity.

1d

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

2d

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday ...

1d

Has Eli Lilly Stock Peaked?

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

13h

Eli Lilly price target lowered to $970 from $1,050 at Berenberg

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

3don MSN

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Insider Monkey2d

Why Eli Lilly (LLY) Stock Is Declining Today

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced ...

1d

Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results